CRIS Current Research Information System

ARDIZZONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.352
EU - Europa 8.015
AS - Asia 5.279
AF - Africa 623
SA - Sud America 12
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
Totale 27.296
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.328
GB - Regno Unito 2.429
CN - Cina 1.940
IT - Italia 1.592
SG - Singapore 1.323
VN - Vietnam 1.124
DE - Germania 1.113
SE - Svezia 867
IN - India 649
IE - Irlanda 409
RU - Federazione Russa 405
FR - Francia 354
TG - Togo 238
ZA - Sudafrica 217
EE - Estonia 211
CH - Svizzera 170
UA - Ucraina 139
CI - Costa d'Avorio 110
FI - Finlandia 104
JO - Giordania 76
BG - Bulgaria 65
ID - Indonesia 45
NG - Nigeria 45
NL - Olanda 37
HK - Hong Kong 35
BE - Belgio 26
CA - Canada 21
AT - Austria 17
JP - Giappone 16
GR - Grecia 13
ES - Italia 12
LB - Libano 12
AU - Australia 10
IR - Iran 10
TR - Turchia 9
UZ - Uzbekistan 9
HR - Croazia 8
PL - Polonia 8
RO - Romania 6
SC - Seychelles 6
BR - Brasile 5
EG - Egitto 5
HU - Ungheria 5
IL - Israele 5
KR - Corea 5
CZ - Repubblica Ceca 4
LT - Lituania 4
PK - Pakistan 4
PT - Portogallo 4
CL - Cile 3
EU - Europa 3
MK - Macedonia 3
SA - Arabia Saudita 3
SM - San Marino 3
AR - Argentina 2
IQ - Iraq 2
MX - Messico 2
MY - Malesia 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
EC - Ecuador 1
KG - Kirghizistan 1
LU - Lussemburgo 1
LV - Lettonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 27.296
Salva come PNG Salva come JPEG
Città #
Southend 2.227
Fairfield 1.891
Singapore 1.169
Ashburn 1.086
Houston 995
Chandler 965
Woodbridge 945
Seattle 815
Wilmington 793
Cambridge 685
Dong Ket 614
Princeton 581
Santa Clara 575
Boardman 429
Ann Arbor 411
Dublin 407
Bologna 397
Lomé 238
Westminster 228
Shanghai 222
Nanjing 211
Padova 167
Beijing 144
San Diego 144
Bern 141
Berlin 122
Redmond 119
Jinan 114
Abidjan 110
Shenyang 109
Medford 108
Saint Petersburg 107
Helsinki 97
Changsha 80
Amman 76
Milan 74
Turin 71
Nanchang 70
New York 68
Tianjin 63
Hebei 60
Sofia 60
Falls Church 59
Jiaxing 50
Bremen 48
Florence 47
Abeokuta 45
Redwood City 45
Zhengzhou 45
Bühl 43
Dearborn 43
Jakarta 43
Guangzhou 42
Norwalk 40
Rome 40
Des Moines 39
Los Angeles 34
London 33
Olalla 30
Hong Kong 28
Ningbo 28
Hangzhou 27
Taiyuan 27
Vicenza 27
Brussels 25
Hyderabad 23
Cinquefrondi 22
Wuhan 21
Messina 20
Shenzhen 20
Taizhou 20
Boydton 19
Haikou 19
Paris 19
Naples 16
Phoenix 16
Lanzhou 15
Shijiazhuang 15
Toronto 15
Casalecchio di Reno 14
Fuzhou 14
Chicago 13
Harbin 13
Xi'an 13
Pune 12
Forlì 11
Frankfurt Am Main 11
Groningen 11
Kunming 11
Moncalieri 11
Moscow 11
Qingdao 11
Tappahannock 11
Modena 10
San Jose 10
Chengdu 9
Hefei 9
Vienna 9
Costa Mesa 8
Lausanne 8
Totale 19.366
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 316
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 194
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 180
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 178
11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel 173
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 160
Circulating tumor cells in genitourinary tumors 157
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) 153
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy 148
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 147
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer 145
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 145
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 143
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer 142
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 142
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study 140
Activity and Safety of Dose-Adjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With Poor-Prognostic Untreated Diffuse Large B-Cell Non-Hodgkin Lymphoma 139
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 136
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 135
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 135
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 135
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 133
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 132
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 131
Second-line treatment of advanced non-small cell lung cancer 130
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 128
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 127
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 127
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 127
Immune-mediated cholangitis: is it always nivolumab’s fault? 127
Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST 127
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins 125
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 125
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 125
The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 125
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 124
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 123
ALK rearrangement testing by fish analysis in non-small-cell lung cancer patients: Results of the first Italian external quality assurance scheme 121
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 121
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 120
null 119
Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response 119
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 117
Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study 116
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 116
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases 116
Chemotherapy treatment in malignant pleural mesothelioma: A difficult history 116
Immune checkpoint inhibitors for metastatic bladder cancer 116
Colorectal cancer patient on maintenance dialysis successfully treated with cetuximab 115
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 115
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 115
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 114
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches 114
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 113
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH 112
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 112
Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer 112
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 111
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 111
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 110
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 110
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma 110
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 110
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis 109
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) 109
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): An open-label randomised controlled phase 3 trial 109
Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study 108
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin 108
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 108
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma 107
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) 107
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy 107
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials 106
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? 106
Complete spontaneous remission of non-small-cell lung cancer: a case report 106
Next-generation technologies in predictive molecular pathology of lung cancers 106
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study 105
Predictive biomarkers of immunotherapy for non-small cell lung cancer: Results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology 104
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 103
Colony-stimulating factors for febrile neutropenia 103
Combination of target agents: Challenges and opportunities 103
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: Does cisplatin versus carboplatin make a difference? 103
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non-small Cell Lung Cancer? 103
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 103
Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites 102
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers 102
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification 101
First LineTreatment in advanced non small-cell lung cancer: the emerging role of the histologic subtype 101
Functional characterization of gefitinib uptake in non small cell lung cancer cell lines 101
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study 101
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 101
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program 101
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 100
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 100
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab 100
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 99
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 99
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 99
Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer 99
Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides 99
Totale 12.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.933
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.018 0 0 0 0 0 0 879 945 908 517 443 326
2020/20213.827 642 231 73 59 285 129 95 217 427 209 148 1.312
2021/20224.862 428 169 322 249 550 247 139 536 275 195 933 819
2022/20235.163 431 694 264 635 454 411 250 313 906 130 354 321
2023/20241.749 155 274 106 147 120 235 64 274 69 137 109 59
2024/20253.844 269 1.111 613 484 952 400 15 0 0 0 0 0
Totale 28.165